Brain Natriuretic Peptide Levels and Cardiac Functional Capacity in Patients With Dyspnea and Isolated Diastolic Dysfunction

Eroğlu, Serpil; Yildirir, Aylin; Bozbaş, Hüseyin; Aydinalp, A.; Ulubay, Gaye; Eldem, Olcay; Simsek, Vahide; Özin, Bülent; Müderrisoğlu, Haldun

doi:10.1536/ihj.48.97

Cited by 10 publications

(12 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study by Serpil, et al revealed that plasma BNP levels provided an indication about the cardiac functional capacity in patients admitted with diastolic dysfunction. 20) Considering these results, we speculate that pitavastatin may improve signs and symptoms of HF.…”

Section: Discussionmentioning

confidence: 86%

Beneficial Effects of Pitavastatin, a 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase Inhibitor, on Cardiac Function in Ischemic and Nonischemic Heart Failure

et al. 2008

View full text Add to dashboard Cite

SUMMARYHMG-CoA reductase inhibitors (statins) have recently been reported to improve cardiac function, and decrease the incidence of heart failure (HF) in hyperlipidemic patients. However, evidence for statin treatment in patients with HF remains a subject of debate. Thus, a study was initiated to examine the effects of pitavastatin on cardiac function evaluated by echocardiographic findings and plasma brain natriuretic peptide (BNP) levels in patients with HF. Twenty-three patients with HF were treated with pitavastatin 1-2 mg/ day in addition to standard therapy for 7.5 ± 3.8 months. Left ventricular end-diastolic dimension (LVDd) and left ventricular end-systolic dimension (LVDs) were determined by echocardiography. Left ventricular ejection fraction (LVEF) was calculated using Teichholz's formula. Serum lipid and plasma BNP levels were also measured. During the follow-up period, LVEF was increased from 42 ± 11 to 48 ± 13% (P = 0.002). LVDs was reduced from 43 ± 10 to 40 ± 10 mm (P < 0.001), while there was no change in LVDd. E/A (n = 10) and deceleration time (n = 7), obtained in some patients, did not change significantly (0.89 ± 0.33 to 0.77 ± 0.17%, and 215 ± 46 to 227 ± 72 msec, respectively). In addition, the plasma BNP level was moderately, but significantly decreased from 94 ± 78 to 70 ± 56 pg/mL (P = 0.005). In subgroup analysis, LVEF was improved in both patients with ischemic and nonischemic HF. There was no significant correlation between the percent change in serum total cholesterol and the percent change in LVEF by pitavastatin treatment. Serum total cholesterol, LDL-cholesterol, and triglycerides decreased by 21%, 30%, and 15%, respectively, and HDL-cholesterol increased by 12%. Pitavastatin improved cardiac function in patients with HF, which generally worsens with time. The results suggest that pitavastatin may be beneficial for treatment of HF. (Int Heart J 2008; 49: 49-58)

show abstract

Section: Discussionmentioning

confidence: 86%

Beneficial Effects of Pitavastatin, a 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase Inhibitor, on Cardiac Function in Ischemic and Nonischemic Heart Failure

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Also, we did not measure brain natriuretic peptide, the level of which has been recently shown to be indicative of the severity of IDD. 22) Besides being cross-sectional, this study was not a prospective population-based randomized investigation, but rather a retrospective observational study of individuals presenting to outpatient clinics; therefore, the potential for selection bias cannot be excluded. However, besides the aforementioned unique geo-demographic characteristic of the study area, this work was performed at 2 large community-based hospitals, thus this sample may largely represent the typical population with cardiac dysfunction seen by a general practitioner.…”

Section: )mentioning

confidence: 99%

Comparative Analysis of Systolic and Isolated Diastolic Dysfunction Sado Heart Failure Study

et al. 2008

View full text Add to dashboard Cite

SUMMARYDetermining the type of cardiac dysfunction is important for implementing therapeutic strategies and for prognostic insights. We characterized systolic dysfunction (SD) and isolated diastolic dysfunction (IDD) in adults referred for echocardiographic evaluation, and compared their clinical and other characteristics. In the present work, we studied 218 patients (137 males) with cardiac dysfunction (mean age, 66.3 ± 8.3 years). SD was defined as a left ventricular ejection fraction (LVEF) of < 45%, whereas IDD was defined as a LVEF ≥ 45% in addition to the standard Doppler-echocardiography diagnostic criteria for IDD. Approximately 68% of subjects had SD (70% males). The proportions of hypertension, diabetes, and dyslipidemia were 44%, 26%, and 22%, respectively, without significant association with the type of dysfunction. Myocardial infarction (MI) was found in 31% of patients, and was significantly (P < 0.001) more prevalent among SD compared with IDD cases. Cerebral stroke (18%) and malignancy (16%) were significantly associated with IDD (29% versus 13% for SD in the case of stroke, and 26% versus 11% for SD in the case of malignancy; P = 0.008 for each). In multivariately-adjusted logistic regression analysis, the following variables were found to be significantly (P < 0.05) and independently associated with IDD: female gender (odds ratio 769-4.808]) was independently associated with SD. In conclusion, some factors/comorbidities were more likely to associate with IDD (female gender, stroke, and malignancy) or SD (previous MI) when IDD and SD were compared with each other. (Int Heart J 2008; 49: 459-469) [

show abstract

“…Kruger et al (34) have also found negative correlation between serum BNP level with PVO 2 and AT values in 70 patients with congestive heart failure. Eroğlu et al (35) evaluated the relationship between BNP levels and CPET parameters in patients with dyspnea and isolated left ventricle diastolic dysfunction and found negative correlation between BNP levels and duration of exercise, AT VO 2 , and MET on CPET. To the best of our knowledge, this is the first study using CPET, and BNP levels in COPD patients.…”

Section: Discussionmentioning

confidence: 99%

Effects of right ventricular dysfunction on exercise capacity and quality of life and associations with serum NT-proBNP levels in COPD: an observational study

Özdemirel¹,

Ulaşlı²,

Yetis³

et al. 2014

Anadolu Kardiyol Derg

Self Cite

View full text Add to dashboard Cite

Objective: During the course of chronic obstructive pulmonary disease (COPD), pulmonary hypertension (PH) and right ventricular (RV) failure may develop due to elevated afterload of the RV. In those patients, exercise capacity is reduced due to pulmonary and cardiac limitations. We investigated relationships between serum N-terminal of proB-type natriuretic peptide (NT-proBNP) and RV functions with exercise capacity and quality of life in patients COPD.Methods: An observational case-control study was conducted. We enrolled 31 moderate and severe COPD patients, and 20 subjects without chronic diseases as control group. Parameters reflecting the right ventricular diastolic and systolic functions by echocardiography along with serum NT-proBNP levels were assessed. Cardiopulmonary exercise testing and Short Form-36 (SF-36) were applied. Results: Serum NT-proBNP levels were higher in COPD patients than control group (p=0.003). Serum NT-proBNP level was found to be related with pulmonary arterial pressure. Serum NT-proBNP levels were negatively correlated with anaerobic threshold oxygen uptake (AT VO 2 ) and peak oxygen uptake (PVO 2 ) values. Early ventricular filling velocity (Em) was lower in COPD patients. Em wave was significantly correlated with O 2 pulse. There was a positive relationship between tricuspid E/A ratio and VO 2 value at AT. SF-36 domains of physical functioning, general health and role limitation due to physical disorder were significantly correlated with AT VO 2 , PVO 2 and O 2 pulse. Conclusion: Exercise limitation may be predicted by assessment of right ventricule functions and NT-proBNP levels and exercise limitation impairs quality of life in COPD patients.

show abstract

Brain Natriuretic Peptide Levels and Cardiac Functional Capacity in Patients With Dyspnea and Isolated Diastolic Dysfunction

Cited by 10 publications

References 25 publications

Beneficial Effects of Pitavastatin, a 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase Inhibitor, on Cardiac Function in Ischemic and Nonischemic Heart Failure

Beneficial Effects of Pitavastatin, a 3-Hydroxy-3-Methylglutaryl Coenzyme a Reductase Inhibitor, on Cardiac Function in Ischemic and Nonischemic Heart Failure

Comparative Analysis of Systolic and Isolated Diastolic Dysfunction Sado Heart Failure Study

Effects of right ventricular dysfunction on exercise capacity and quality of life and associations with serum NT-proBNP levels in COPD: an observational study

Contact Info

Product

Resources

About